Literature DB >> 23721720

Biological activity and biotechnological aspects of locked nucleic acids.

Karin E Lundin1, Torben Højland, Bo R Hansen, Robert Persson, Jesper B Bramsen, Jørgen Kjems, Troels Koch, Jesper Wengel, C I Edvard Smith.   

Abstract

Locked nucleic acid (LNA) is one of the most promising new nucleic acid analogues that has been produced under the past two decades. In this chapter, we have tried to cover many of the different areas, where this molecule has been used to improve the function of synthetic oligonucleotides (ONs). The use of LNA in antisense ONs, including gapmers, splice-switching ONs, and siLNA, as well as antigene ONs, is reviewed. Pharmacokinetics as well as pharmacodynamics of LNA ONs and a description of selected compounds in, or close to, clinical testing are described. In addition, new LNA modifications and the adaptation of enzymes for LNA incorporation are reviewed. Such enzymes may become important for the development of stabilized LNA-containing aptamers.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23721720     DOI: 10.1016/B978-0-12-407676-1.00002-0

Source DB:  PubMed          Journal:  Adv Genet        ISSN: 0065-2660            Impact factor:   1.944


  35 in total

1.  Cooperative hybridization of γPNA miniprobes to a repeating sequence motif and application to telomere analysis.

Authors:  Ha H Pham; Connor T Murphy; Gopalsamy Sureshkumar; Danith H Ly; Patricia L Opresko; Bruce A Armitage
Journal:  Org Biomol Chem       Date:  2014-10-07       Impact factor: 3.876

Review 2.  Recent advances in RNAi-based strategies for therapy and prevention of HIV-1/AIDS.

Authors:  Manjunath N Swamy; Haoquan Wu; Premlata Shankar
Journal:  Adv Drug Deliv Rev       Date:  2016-03-21       Impact factor: 15.470

3.  In Vitro Silencing of lncRNAs Using LNA GapmeRs.

Authors:  Elisa Taiana; Vanessa Favasuli; Domenica Ronchetti; Eugenio Morelli; Pierfrancesco Tassone; Giuseppe Viglietto; Nikhil C Munshi; Antonino Neri; Nicola Amodio
Journal:  Methods Mol Biol       Date:  2021

Review 4.  RNA therapy: Are we using the right molecules?

Authors:  Ai-Ming Yu; Chao Jian; Allan H Yu; Mei-Juan Tu
Journal:  Pharmacol Ther       Date:  2018-12-04       Impact factor: 12.310

5.  RNA therapeutics: RNAi and antisense mechanisms and clinical applications.

Authors:  Jessica Chery
Journal:  Postdoc J       Date:  2016-07

6.  Allele-selective inhibition of expression of huntingtin and ataxin-3 by RNA duplexes containing unlocked nucleic acid substitutions.

Authors:  Yuichiro Aiba; Jiaxin Hu; Jing Liu; Qin Xiang; Carlos Martinez; David R Corey
Journal:  Biochemistry       Date:  2013-11-27       Impact factor: 3.162

7.  Methods and compositions for amplification and detection of microRNAs (miRNAs) and noncoding RNAs (ncRNAs) using the signature sequence amplification method (SSAM).

Authors:  Stephen D Ginsberg; Shaoli Che
Journal:  Recent Adv DNA Gene Seq       Date:  2014

8.  2'-O-(N-(Aminoethyl)carbamoyl)methyl Modification Allows for Lower Phosphorothioate Content in Splice-Switching Oligonucleotides with Retained Activity.

Authors:  Dmytro Honcharenko; Cristina S J Rocha; Karin E Lundin; Jyotirmoy Maity; Stefan Milton; Ulf Tedebark; Merita Murtola; Malgorzata Honcharenko; Andis Slaitas; C I Edvard Smith; Rula Zain; Roger Strömberg
Journal:  Nucleic Acid Ther       Date:  2022-03-02       Impact factor: 4.244

Review 9.  Novel approaches for efficient  in vivo fermentation production of noncoding RNAs.

Authors:  Ai-Ming Yu; Neelu Batra; Mei-Juan Tu; Colleen Sweeney
Journal:  Appl Microbiol Biotechnol       Date:  2020-01-17       Impact factor: 4.813

10.  Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia model.

Authors:  Burcu Bestas; Pedro M D Moreno; K Emelie M Blomberg; Dara K Mohammad; Amer F Saleh; Tolga Sutlu; Joel Z Nordin; Peter Guterstam; Manuela O Gustafsson; Shabnam Kharazi; Barbara Piątosa; Thomas C Roberts; Mark A Behlke; Matthew J A Wood; Michael J Gait; Karin E Lundin; Samir El Andaloussi; Robert Månsson; Anna Berglöf; Jesper Wengel; C I Edvard Smith
Journal:  J Clin Invest       Date:  2014-08-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.